Figures at a glance

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

FIGURE 1

Figure1: Whole framework based on network pharmacology

FIGURE 2

Figure 2: Active Ingredients of EZP: orange represents LLF, pink represents EH, and red represents the same active ingredients

FIGURE 3

Figure3: POI gene prediction analysis

FIGURE 4

Figure4: the common targets of EZP and POI

FIGURE 5

Figure5: Drug active ingredients and disease target network

FIGURE 6

Figure6: Protein-Protein interaction network

FIGURE 7

Figure7: Process of topological screening for the PPI network

FIGURE 8

Figure8: GO enrichment of EZP active components in the treatment of common targets of POI

FIGURE 9

Figure 9: Enriched KEGG pathways of potential targets for treating POI from the main active ingredients of EZP

FIGURE 10

Figure 10: Molecular docking of compounds with core targets. (a) Docking process of quercetin with AKT1; (b) Docking process of quercetin with TP53; (c) Docking process of quercetin with MAPK1; (d) Docking process of quercetin with TNF; (e) Docking process of quercetin with JUN; (f) Docking process of quercetin with RB1; (g) Docking process of quercetin with MYC